Peter is Director or the Pandemic Sciences Institute Moh Family Foundation and Professor of Emerging Infectious Diseases and Global Health.

Peter trained in medicine at University College London and went on to specialise in emerging and epidemic prone infectious diseases. Over the last 20 years, he has led research on a wide range of emerging and epidemic infections, including SARS, avian influenza, Ebola, Lassa fever, plague and COVID-19.

Peter is Director of the recently established Pandemic Sciences Institute and also Executive Director of the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC), a consortium of 53 international, national and local research networks whose research activities span 134 countries worldwide.

Peter co-leads the RECOVERY trial of treatments for COVID-19, which has randomised over 47,000 participants and evaluated 13 drugs. RECOVERY is open to recruitment in eight countries and has extended to include the evaluation of treatments for influenza.

Darren is Principal Statistician of the Health Research Board Clinical Research Facility, Cork, and a Senior Lecturer in Patient-Focused Research Methods at the School of Public Health, University College Cork (UCC). In these roles, he consults and collaborates on a wide portfolio of patient-focused and public health research, including more than a dozen investigator-led clinical trials. Darren also teaches postgraduate students about clinical trial study design and analysis, reproducible research methods, and critical appraisal skills. Prior to joining UCC, he lecturer in epidemiology and biostatistics at the University of Leeds. Darren earned a PhD in Epidemiology from the University of North Carolina in 2008 and a Masters in International Health Science from the Johns Hopkins School of Public Health, Baltimore, Maryland in 2002.

Rachael is an Associate Professor leading a research group in the University of Oxford developing experimental and computational methods in B and T cell receptor sequencing, single cell multi-omics, and functional assays. The group aims to determine the development, regulation, and function of B and T cell populations in health and immunological diseases, disease susceptibility, and effect of therapy. This is being achieved through the development and application of novel experimental and computational approaches, working in partnership with a global network of clinicians, immunologists and sample cohorts. Rachael is also a co-founder of Alchemab Therapeutics, which is working to develop transformative therapies.

Anjali is a group leader and Sir Henry Dale Fellow, supported by the Wellcome Trust and Royal Society. She was awarded the Wellcome Beit Prize in 2021.

Anjali is interested in germline DNA changes, which include de novo mutation and recombination. Her lab uses a combination of computational and experimental approaches towards understanding the biological mechanisms underlying mutation and recombination, and their impacts on human health and the evolution of species.

Originally from the Czech Republic, I did my bachelor's in Cell Biology at UCL, followed by a Master’s in Integrated Immunology at Oxford. I am currently completing a DPhil in Clinical Medicine at the Pandemic Sciences Institute, supervised by Professor Dame Sarah Gilbert, and supported through the NDM Prize and Phillips Scholarships. My focus is on viral-vectored vaccines and improvements to the underlying platform technology. In my free time, I also mentor underprivileged children within IntoUniversity. 

Hashem is an Associate Professor of Systems Immunology at the MRC Weatherall Institute of Molecular Medicine (MRC WIMM), University of Oxford. He leads a research group that aims to understand the fundamental principles of the adaptive immunity using integrative machine learning approaches applied to emerging single-cell sequencing data. His group is specifically interested in decoding the rules of antigen-specific T cell response in time and space.

Aleks is a Product Owner at Exscientia, a leading AI-driven drug discovery company based in Oxford. Aleks has a diverse background in research and science, which he brings to his current role at Exscientia. He completed his interdisciplinary DPhil at Oxford University in the Department of Statistics in 2021, and went on to work as a Data Scientist at a London-based start-up called LabGenius. After 1.5 years at LabGenius, Aleks joined Exscientia as a research scientist before moving into his current role as a product owner. With his expertise in both research and product development, Aleks is dedicated to driving innovation and improving the efficiency of drug discovery through the use of cutting-edge AI technology.

Francesca graduated in Mathematics at the University of Torino and Collegio Carlo Alberto (Italy). She obtained her PhD in Statistics in 2022 at the University of Oxford. During the PhD, she internet at IDSIA Lugano (Switzerland) and J. P. Morgan in London. In July 2022, she joined the Department of Statistics of the London School of Economics and Political Science as Assistant Professor, where her research focuses on Bayesian modelling for networks and privacy, fair ML and she teaches Deep Learning.

Clare West is a computational biologist with experience in structural biology and drug discovery, currently a Principal Scientist at Benevolent AI. Her postdoctoral research aimed to identify and prioritise tractable drug targets within the mechanisms linking ageing and age-related diseases, in collaboration with UK SPINE, the Centre for Medicines Discovery (CMD), and Open Targets at EMBL-EBI. She has a BSc in Biochemistry (University of Nottingham) and a PhD in Protein Informatics (Department of Statistics, University of Oxford) focussing on template-free protein structure prediction.